文献速递胃肠外科围术期管理与 ERAS

药物与手术治疗GERD患者的CYP2C19多态性患病率

Prevalence of CYP2C19 polymorphisms in medically and surgically managed patients with GERD.
PubMed 文献 · Surgery · 2026-05-05

这项多中心回顾性队列研究纳入138例有CYP2C19检测结果的成人GERD患者,比较药物管理与抗反流手术患者的CYP2C19表型分布。

要点

  • 抗反流手术患者中CYP2C19快速/超快速代谢者占43%,显著高于药物组的24%。
  • 快速/超快速代谢者PPI疗效可能不足,应考虑剂量递增或及时转诊手术。
  • CYP2C19检测有望优化GERD的药物与手术治疗决策。

核心结论

  • 接受抗反流手术的患者中CYP2C19快速/超快速代谢者比例显著高于药物管理的GERD患者。

研究设计与样本

  • 多中心回顾性队列研究,纳入2012至2023年电子健康记录中有CYP2C19检测结果的138例成人患者,药物组58例、手术组80例。

主要发现

  • 药物组以正常代谢者为主,占54%(n=31)。
  • 手术组中poor/intermediate代谢者占27%(n=22),normal代谢者占30%(n=24)。
  • 小号(n=41)和中号(n=21)食管裂孔疝患者中多数为快速或超快速代谢者,分别占39%和57%。

关键数值与推荐

  • pH阳性定义为酸暴露时间>6%或DeMeester评分>14.7。
  • 药物组平均酸暴露时间为15.3%,DeMeester评分中位数为33(21-69)。
  • 食管裂孔疝大小根据影像、内镜和术中所见分为小、中、大三类。

临床怎么用

  • 对CYP2C19快速/超快速代谢的GERD患者,可考虑递增PPI剂量以获得疗效。
  • 若剂量递增后仍无效,应及时转诊评估抗反流手术。
  • CYP2C19检测有潜力辅助GERD个体化药物与手术决策。

局限性

  • 回顾性研究设计,样本量有限(共138例),需前瞻性多中心研究验证CYP2C19检测的临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The medical therapy of gastroesophageal reflux disease relies predominantly on proton pump inhibitors, with surgery recommended for patients refractory to medical therapy and/or those with symptomatic hiatal hernias. Proton pump inhibitor plasma concentration, and thus the effectiveness and safety of proton pump inhibitors, are dependent on metabolism by cytochrome P450 2C19 (CYP2C19) in the liver. CYP2C19 polymorphisms and resultant enzyme activity influence plasma concentrations of proton pump inhibitors. For patients who are rapid metabolizers (2%-27% of patients) or ultrarapid metabolizers (<1%-5%) of proton pump inhibitors, dose escalation is recommended to obtain therapeutic benefit. Poor (1%-8%) or intermediate (20%-46%) metabolizers of proton pump inhibitors have increased drug effectiveness at lower doses but are at a higher risk of experiencing side effects. This study aimed to determine the prevalence of CYP2C19 phenotypes in medically and surgically managed patients. We hypothesized that surgical patients would have a higher prevalence of rapid and ultrarapid metabolizer phenotype, making them resistant to proton pump inhibitors compared with the medical patients. METHODS: This was a multisite retrospective cohort study of adult patients with CYP2C19 test results identified in their electronic health record from 2012 to 2023. The medically managed group included gastroesophageal reflux disease patients with positive pH testing, whereas the surgically managed group included patients who underwent antireflux surgery. CYP2C19 phenotypes were categorized as poor/intermediate, normal, or rapid/ultrarapid metabolizer. A positive pH test was defined as acid exposure time >6% or DeMeester score >14.7. Hiatal hernia size was classified as small, medium, or large based on imaging, endoscopy, and intraoperative findings. Descriptive statistics were used to characterize the metabolization status. RESULTS: A total of 138 patients were included in this study: 58 medical patients (female: 59%, median age 62 years [interquartile range 46-68], 84% White) and 80 surgical patients (female: 66%, median age 61 years [interquartile range 53-67], 90% White). In the medical cohort, the mean acid exposure time was 15.3% and the median DeMeester score was 33 (21-69). The majority of medical patients were normal metabolizers (54%, n = 31). In the surgical cohort, 27% (n = 22) were poor or intermediate metabolizers, 30% (n = 24) were normal metabolizers, and 43% (n = 34) were rapid/ultrarapid metabolizers. Surgical patients had a higher prevalence of CYP2C19 rapid/ultrarapid metabolizer phenotypes compared with medical patients, 43% (n = 34) vs 24% (n = 14) (P = .02). Among patients with small- (n = 41) and medium-sized (n = 21) hiatal hernias, the majority were classified as rapid or ultrarapid metabolizer (39% and 57% with small and medium hernias, respectively), suggesting resistance to proton pump inhibitors. Additionally, surgical patients were significantly more likely to have medium- and large-sized hiatal hernias compared with medical patients (P < .01). CONCLUSIONS: Surgical patients who underwent antireflux surgery had a higher prevalence of rapid/ultrarapid metabolizer CYP2C19 phenotypes compared with medical patients. These data suggest that proton pump inhibitor dose should be escalated in medical patients with these phenotypes, and if ineffective, a timely referral should be made for surgical management. This is one of the first studies assessing the pharmacogenomic CYP2C19 test in adult patients with gastroesophageal reflux disease. CYP2C19 testing has immense potential to optimize medical and surgical management of patients with gastroesophageal reflux disease, and prospective multisite studies are needed to confirm utility of the test.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Naser AR, Pather K, Mobley EM, et al. Prevalence of CYP2C19 polymorphisms in medically and surgically managed patients with GERD. Surgery. 2026. PMID: 42259674. doi:10.1016/j.surg.2026.110296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。